Inhibition of SARS-CoV-2 infection by vaccine-induced antibodies and small-interfering RNAs
- Weitere Titel
-
Hemmung der SARS-CoV-2-Infektion durch Impfstoff-induzierte Antikörper und small-interfering RNAs
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
München, Technische Universität München, Dissertation, 2023
- Schlagwort
-
COVID-19
SARS-CoV-2
Pandemie
Impfstoff
Pathogenese
Virusinfektion
- Ereignis
-
Veröffentlichung
- (wo)
-
München
- (wer)
-
Universitätsbibliothek der TU München
- (wann)
-
2023
- Urheber
-
Cheng, Cho-Chin
- Beteiligte Personen und Organisationen
- URN
-
urn:nbn:de:bvb:91-diss-20231023-1716484-1-9
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:41 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cheng, Cho-Chin
- Protzer-Knolle, Ulrike
- Ehmer, Ursula
- Rad, Radu Roland
- Keppler, Oliver T.
- Universitätsbibliothek der TU München
Entstanden
- 2023
Ähnliche Objekte (12)
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2
The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles
Generation and Characterization of Monoclonal Antibodies directed against SARS-CoV-2
Management of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity
Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity
Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity
Vaccine response against SARS-CoV-2 under immunomodulatory systemic therapies in dermatology
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2
The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles
Generation and Characterization of Monoclonal Antibodies directed against SARS-CoV-2
Management of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity
Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity
Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity
Vaccine response against SARS-CoV-2 under immunomodulatory systemic therapies in dermatology
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2
The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles
Generation and Characterization of Monoclonal Antibodies directed against SARS-CoV-2
Management of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity
Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity
Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity
Vaccine response against SARS-CoV-2 under immunomodulatory systemic therapies in dermatology